"At Acuity Pharmaceuticals we faced many challenges back in 2003. Five years later, we can view our scientific and financial successes with the benefit of hindsight to seek the contributing factors to that success. BioAdvance was one of the first companies we presented our company to. We received quick feedback and then were involved in a thorough diligence process which gave us more input and encouragement. At that early juncture, BioAdvance decided to invest, yet it was far more than money that made the difference. The BioAdvance team provided contacts and an effective sounding board for our development during those formative years."
Dale Pfost
Former CEO
Acuity Pharmaceuticals
Philadelphia, PA
Dale Pfost
Former CEO
Acuity Pharmaceuticals
Philadelphia, PA
BioAdvance and Portfolio News Coverage
| 2012 | | | 2011 | | | 2010 | | | 2009 | | | 2008 | | | 2007 | | | 2006 | | | 2005 | | | 2004 | | | 2003 | | | 2002 | | | 2001 |
2012
|
February 3, 2012
Human monoclonal antibody firm collaborating with Big Pharma |
| > View Article |
|
February 2, 2012
Niiki Pharma Forms Scientific Advisory Board with Leading U.S. Oncologists |
| > View Article |
|
January 18, 2012
Ceptaris Therapeutics Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel |
| > View Article |
|
January 18, 2012
Ceptaris cutaneous T-cell lymphoma drug gets Europe orphan status |
|
January 13, 2012
PhillyInc: 2012 sees early twists in Phila. region's life-sciences sector |
| > View Article |
|
January 13, 2012
Niiki Pharma developing new weapons |
| > View Article |
|
January 5, 2012
Yaupon Changes Name to Ceptaris Therapeutics, Inc. |
| > View Article |
|
January 3, 2012
Ossianix Announces Lundbeck Investment |
| > View Article |
© Copyright 2008. BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania. All Rights Reserved.